Abstract:Divya Ail, Hugo Malki, Emilia A Zin, Deniz Dalkara Sorbonne Université, INSERM, CNRS, Department of Therapeutics, Institut de la Vision, Paris, 75012, France Correspondence: Divya Ail, Department of Therapeutics, Institut de la Vision, 17 Rue Moreau, Paris, 75012, France, Tel +33 153462648, Email Owing to their small size and safety profiles, adeno-associated viruses (AAVs) have become the vector of choice for gene therapy applications in the retina. In addition to the naturally occurring AAVs, several engineered variants with enhanced properties are being developed for experimental and therapeutic applications. Nonetheless, there are still some challenges impeding successful application of AAVs for a broader range of retinal gene therapies. The small size of AAV particles ensures efficient tissue transduction but also limits the packaging capacity to a few kilobases. Further, AAV's ability to cross retinal barriers is still an obstacle to pan-retinal transduction of the outer retina with tolerable doses. Lastly, despite overall safety, there have been recent reports of immune responses to AAVs in the eye. Hence, evaluation and prediction of immune responses to AAVs has come to be considered an integral part of future clinical success. This review focuses on the use of AAV in clinical trials for retinal diseases, and discusses developments of variants and novel strategies to overcome immune responses to AAVs. Keywords: retinal gene therapy, adeno-associated virus, AAV, clinical trials, capsid variants, immune responses AAVs are non-pathogenic viruses belonging to the Parvoviridae family under the genus Dependoparvovirus . They can infect humans but are non-pathogenic and are known to have low immunogenicity. They are naturally replication-deficient and hence termed as 'helper-dependent virus' as they depend on the presence of adenovirus, herpesvirus or papilloma virus as helpers to replicate. 1–3 In the absence of a 'helper virus' AAV remains latent by integrating into the host genome or remaining as extrachromosomal episomes. AAVs are small, non-enveloped viruses with a capsid size of 25nm and package single-stranded DNA of approximately 4700 base pairs. 4 There are 13 naturally occurring AAV serotypes (AAV1 – AAV13) and 100s of AAV variants have been identified or engineered. These AAV serotypes possess distinct tropisms that are tissue specific and species specific. The tissue tropism/specificity of AAVs is determined by the proteins on the surface of capsids. The capsid proteins bind specific cell-surface receptors which in turn recruit co-receptors leading to internalization by endocytosis into the cell. 5 Following internalization AAVs escape the endosomes and gain entry into the nucleus. 6 AAV relies on the host cell mechanisms for the second strand synthesis. 7 For experimental and clinical applications recombinant AAVs (rAAV) are created by replacing the viral genome by the transgene of interest while retaining the ITRs. The ITRs flank the transgene and ensure its encapsidation within the AAV. The other structural (capsid proteins) and non-structural (replication and helper) genes are supplied separately. 4,8 rAAVs rarely integrate into the host cell genome, thereby reducing the risk of insertional mutagenesis following gene therapy. Gene therapy refers to the introduction of genetic material into tissues to rectify the effects of disease-causing mutations. Inherited diseases caused by gene mutations resulting in deficiency or malfunction of proteins involved in cellular functions are ideal targets for gene therapy. Such diseases can be treated by replacement of the entire defective gene, silencing of the mutation or correction/editing of the mutation. The therapeutic gene is packaged into AAVs and delivered to target tissue by local injections. 9 AAV delivery to the retina is normally done by two routes: subretinal and intravitreal. Subretinal injection (SRI) involves injection between the Retinal Pigment Epithelium (RPE) and the photoreceptors resulting in efficient AAV delivery to the outer retina. Intravitreal injection (IVT) involves AAV delivery into the vitreous space thereby causing transduction of the Ganglion Cell Layer (GCL) and some other cell types of the inner retina. 10 The retina is an ideal target for gene therapy due to two main reasons: First, many gene mutations responsible for Inherited Retinal Diseases (IRDs) have been identified, 11 and second, the retina is enclosed within the eye in a relatively immune-privileged space. The retina is shielded by a blood-retinal barrier and also benefits from the unique intraocular microenvironment. 12 This prevents the occurrence of a strong systemic effect to the AAV-mediated ocular gene therapy. Over the last five -Abstract Truncated-

Therapeutic homology-independent targeted integration in retina and liver

Safe and effective liver-directed AAV-mediated homology-independent targeted integration in mouse models of inherited diseases

Gene Editing Preserves Visual Functions in a Mouse Model of Retinal Degeneration

Clinical Pharmacology Perspective on Development of Adeno‐Associated Virus Vector‐Based Retina Gene Therapy

Assessment of Pre-Clinical Liver Models Based on Their Ability to Predict the Liver-Tropism of Adeno-Associated Virus Vectors

Directed Evolution of AAV Targeting Primate Retina by Intravitreal Injection Identifies R100, a Variant Demonstrating Robust Gene Delivery and Therapeutic Efficacy in Non-Human Primates

Gene therapy for inherited retinal diseases: exploiting new tools in genome editing and nanotechnology

In Situ Gene Therapy Via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation.

AAV for Gene Therapy in Ocular Diseases: Progress and Prospects

AAV capsid bioengineering in primary human retina models

Mannose-coupled AAV2: a second generation AAV vector for increased retinal gene therapy efficiency

Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?

AAV-Based Strategies for Treatment of Retinal and Choroidal Vascular Diseases: Advances in Age-Related Macular Degeneration and Diabetic Retinopathy Therapies

AAV Gene Transfer with Tandem Promoter Design Prevents Anti-transgene Immunity and Provides Persistent Efficacy in Neonate Pompe Mice

Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy

AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery

A Comparative Analysis of Models for AAV-Mediated Gene Therapy for Inherited Retinal Diseases

Effective AAV-mediated gene replacement therapy in retinal organoids modelling AIPL1-associated LCA4

Optimization strategies and advances in the research and development of AAV‐based gene therapy to deliver large transgenes

Adeno-associated virus therapies: Pioneering solutions for human genetic diseases

AAV-mediated FOXG1 gene editing in human Rett primary cells